So it’s a project in collaboration with Personalis, a California based biotech company that developed an ultra sensitive ctDNA analysis platform, and with that technology, we actually analyzed a patient cohort derived from our center of advanced first line melanoma patients, metastatic melanoma patients that received checkpoint inhibitors, mainly nivo/ipi combination and with a biobanking and a sampling of every 3 to 4 weeks during treatment...
So it’s a project in collaboration with Personalis, a California based biotech company that developed an ultra sensitive ctDNA analysis platform, and with that technology, we actually analyzed a patient cohort derived from our center of advanced first line melanoma patients, metastatic melanoma patients that received checkpoint inhibitors, mainly nivo/ipi combination and with a biobanking and a sampling of every 3 to 4 weeks during treatment. We have a quite granular view on the ctDNA dynamics. This platform is unique in the sense that it is ultra sensitive, meaning it reaches a sensitivity down to one ppm, down to one parts per million, which is just 100 fold lower than, uh, than the sensitivity reached with the standard routine ctDNA measurement. The digital droplet PCR, which reaches 100 ppm per round. So with such an ultra sensitive approach, we were able actually to detect one third more into our cohort of patients with ctDNA levels and get informative information regarding the development of resistance, the development of a deep of a complete response even and therefore significantly associate these patients ctDNA dynamics with the clinical outcome.